Director Jason M. Aryeh filed a Form 144 notice with the SEC on October 30, 2026, proposing to sell 202 shares of Ligand Pharmaceuticals Inc. common stock under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Seller and role: Jason M. Aryeh, listed as a Director of Ligand Pharmaceuticals Inc.
  • Shares proposed for sale: 202 shares of common stock, with an aggregate market value reported as $64,738.00.
  • Original acquisition: The 202 shares were acquired via open market purchase on March 13, 2019, with cash payment on the same date.
  • Broker named: Charles Schwab & Co., Inc., 3000 Schwab Way, Westlake, TX 76262.
  • Approximate sale date: October 30, 2026, on the Nasdaq exchange.
  • Shares outstanding: 19,935,609 shares of common stock reported as outstanding.
  • Prior three-month sales: The filing indicates nothing to report for securities sold during the past three months.

Ligand Pharmaceuticals Director Aryeh Discloses Proposed Rule 144 Share Sale

According to the Form 144 filing, Jason M. Aryeh, a director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), has provided notice of a proposed sale of 202 shares of the company's common stock. The filing identifies the issuer as Ligand Pharmaceuticals Inc., headquartered at 3911 Sorrento Valley Blvd, Suite 110, San Diego, California 92121, with SEC File Number 001-33093.

The filing discloses that the 202 shares proposed for sale were originally acquired through an open market purchase on March 13, 2019, with full cash payment made on that same date. The aggregate market value of the shares to be sold is stated as $64,738.00. The total number of shares of common stock outstanding is reported as 19,935,609. The proposed sale is to be executed through Charles Schwab & Co., Inc., with an approximate sale date of October 30, 2026, on the Nasdaq exchange.

The filing further states that no securities of the issuer were sold by Aryeh during the past three months. By signing the notice, the filer represented, as stated in the form, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." No written trading plan or Rule 10b5-1 instruction date is indicated in the filing.

What Was Disclosed

Director Jason M. Aryeh filed a Form 144 notice on October 30, 2026, proposing to sell 202 shares of Ligand Pharmaceuticals Inc. common stock, originally acquired via open market purchase on March 13, 2019, with an aggregate market value of $64,738.00.